NUWELLIS
ANNOUNCES DATA DEMONSTRATING STATISTICALLY SUPERIOR CLINICAL BENEFIT OF AQUADEX THERAPY IN REDUCING HEART FAILURE EVENTS AND MORTALITY AT THE 2022 HFSA MEETING
Statistically
Significant Reduction in CV Mortality and HF Rehospitalizations as Compared to IV Diuretics at 30 and 90 Days
MINNEAPOLIS, October 3, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the
lives of people with fluid overload, today announced the results of the AVOID-HF clinical study analysis presented at the Heart Failure Society of America’s (HFSA) 2022 Annual Scientific Meeting. The results of the analysis performed using the
Finkelstein-Schoenfeld method of Win-Ratios (WR) demonstrated a statistically superior benefit when using ultrafiltration over diuretics for fluid-overloaded heart failure patients.
“The re-evaluation of AVOID-HF, using the Win-Ratios calculation,
shows that adjustable ultrafiltration is safe and more effective than adjustable IV diuretics in reducing heart failure events for hospitalized heart failure patients,” said Maria DeVita, M.D., Professor of Medicine at Hofstra School of
Medicine/Northwell and Chief of the Division of Nephrology at Lenox Hill Hospital. “The results favored ultrafiltration over diuretics in reducing heart failure events within 30 days and cardiovascular mortality within 90 days. These results give
us great confidence in REVERSE-HF, the ongoing prospective, multicenter, randomized controlled trial.”
The AVOID-HF outcomes were evaluated using a composite endpoint consisting of cardiovascular (CV) mortality within 90 days, heart
failure (HF) events within 30-days, and time-to-first HF event within 90 days. Adjustable Ultrafiltration (AUF) was statistically superior compared to Adjustable IV Loop Diuretics (ALD) with 81% more wins (Win Ratio=1.81, p=0.0429). A secondary
WR analysis was also performed with a composite endpoint consisting of CV mortality within 30 days, HF events within 30-days, and time-to-first HF event within 90 days and found that AUF was statistically superior to ALD with 109% more wins (Win
Ratio=2.09, p=0.0278). Results from this analysis are aligned with multiple systematic reviews that have demonstrated adjustable ultrafiltration to be more effective than diuretics in fluid removal, weight loss, and reducing hospital
readmissions.1-3
“The results of this analysis support the clinical
benefits of providing ultrafiltration with the Aquadex System in reducing readmissions and rehospitalization in fluid overloaded heart failure patients,” said Nestor Jaramillo, Jr., President and CEO of Nuwellis. “The Aquadex System creates the
potential to provide significant cost savings to
hospitals and the health care system, but more importantly, improved quality of life for many patients. We’re grateful to Drs. Pinney, DeVita, and Costanzo, the authors of this manuscript, for leading this reanalysis of the AVOID-HF data.
Nuwellis is committed to making Aquadex therapy the standard of care for fluid management in heart failure patients that are unresponsive to diuretics.”
The AVOID-HF (Aquapheresis Versus Intravenous Diuretics and Hospitalization for Heart Failure) prospective, multicenter, randomized
controlled trial tested the hypothesis that patients hospitalized for heart failure (HF) and treated with ultrafiltration would have a longer time to their first heart failure event within 90 days after hospital discharge compared to those
receiving IV loop diuretics. The study was trending favorably when the study sponsor terminated it before reaching full enrollment for reasons unrelated to patient safety or clinical futility. At the time, analysis of the AVOID-HF trial data was
inconclusive due to the lower-than-planned sample size. However, the Finkelstein-Schoenfeld method of hierarchical Win Ratios increases statistical precision in demonstrating significant differences in clinical outcomes between treatment arms,
while requiring a smaller study sample size.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload
through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly-owned
subsidiary in Ireland.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and predictable method of removing excess fluid
from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients
weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription,
both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are
based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without
limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our
post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products,
potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and
uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
# # #
CONTACTS
INVESTORS:
George Montague, CFA
Chief Financial Officer, Nuwellis, Inc.
ir@nuwellis.com
Leigh Salvo
Gilmartin Group LLC
leigh@gilmartinir.com
MEDIA:
Sarah Lundberg
Health+Commerce
sarahlundberg@healthandcommerce.com
|
1. |
Wang, M.J., et al. Medicine (Baltimore), 2021. 100(50): p. e28029.
|
|
2. |
Wobbe, B., et al. Heart Fail Rev, 2021. 26(3): p. 577-585.
|
|
3. |
Jain, A., et al. Heart Fail Rev, 2016. 21(5): p. 611-9.
|